Negara: Singapura
Bahasa: Inggris
Sumber: HSA (Health Sciences Authority)
MOMETASONE FUROATE MONOHYDRATE EQV MOMETASONE FUROATE
ORGANON SINGAPORE PTE. LTD.
R01AD09
50 mcg/dose
SPRAY
MOMETASONE FUROATE MONOHYDRATE EQV MOMETASONE FUROATE 50 mcg/dose
NASAL
Prescription Only
Organon Heist bv
ACTIVE
1999-02-19
Patient Information Leaflet NASONEX® AQUEOUS NASAL SPRAY 0.05% Mometasone Furoate 50 mcg/dose Please read this leaflet carefully before you start using this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What NASONEX is and what it is used for 2. Before you use NASONEX 3. How to use NASONEX 4. Possible side effects 5. How to store NASONEX 6. Further information 1. WHAT NASONEX IS AND WHAT IT IS USED FOR What is NASONEX? NASONEX Nasal Spray contains mometasone furoate, one of a group of medicines called corticosteroids. Mometasone furoate should not be confused with “anabolic” steroids misused by some athletes and taken as tablets or injections. When tiny amounts of mometasone furoate are sprayed into the nose, it can help to relieve inflammation, sneezing, itching and a blocked up or runny nose. What is NASONEX used for? NASONEX is used in adults and children aged 2 and older to treat the symptoms of seasonal or perennial rhinitis. To help prevent moderate to severe symptoms of seasonal allergic rhinitis, NASONEX may be used 2 to 4 weeks before the beginning of the pollen season. In adults aged 18 and over, NASONEX is also used to treat nasal polyps. NASONEX may also be used in adults and children 12 years of age and older for the treatment of symptoms of acute rhinosinusitis (inflammation and blockage of the sinuses behind the nose) without signs or symptoms of bacterial infection. What is seasonal and perennial rhinitis? Seasonal allergic rhinitis, which occurs at certain times of the year, is an allergic reaction caused by breathing in pollen from trees, grasses, weeds and also moulds and fungal spores. Perennial rhinitis occur Baca dokumen lengkapnya
S-CCDS-MK0887-NS-082017 NASONEX® Aqueous Nasal Spray Brand of mometasone furoate monohydrate FOR INTRANASAL ADMINISTRATION DESCRIPTION: NASONEX Aqueous Nasal Spray is metered-dose, manual pump spray unit containing a suspension of mometasone furoate. Each metered-dose pump actuation of NASONEX Aqueous Nasal Spray delivers approximately 100 mg of mometasone furoate suspension, containing mometasone furoate monohydrate equivalent to 50 micrograms mometasone furoate. Inactive ingredients: Cellulose, glycerol, citric acid monohydrate, sodium citrate dihydrate, polysorbate 80, benzalkonium chloride and purified water. Preservatives: benzalkonium chloride 0.2 mg/g. ACTIONS: Mometasone furoate is a topical glucocorticosteroid with local anti-inflammatory properties at doses that are not systemically active. PRECLINICAL PHARMACOLOGY AND TOXICOLOGY: Preclinical studies demonstrate that mometasone furoate is devoid of androgenic, antiandrogenic, estrogenic or antiestrogenic activity but, like other glucocorticoids, it possesses some antiuterotrophic activity and delays vaginal opening in animal models at high oral doses of 56 mg/kg/day and 280 mg/kg/day. In cell culture, mometasone furoate was shown to be at least ten times more potent than other steroids, including beclomethasone dipropionate (BDP), betamethasone, hydrocortisone and dexamethasone, at inhibiting the synthesis/release of IL-1, IL-6 and TNFα . Mometasone furoate (IC 50 = 0.12 Nm) was also at least six times more potent than BDP and betamethasone at inhibiting IL-5 production. Also, in mixed leukocytes from atopic patients, mometasone was a more potent leukotriene production inhibitor than BDP. In a preclinical model, the compound has been shown to reduce the accumulation of eosinophils markedly at the site of an allergic reaction. For example, in allergic mice with IgE-mediated allergy, inhaled mometasone furoate at doses as low as 10 micrograms/kg inhibited eosinophil infiltration into bronchoalveolar lavage fluid and the lung bronchi and bronchioles. Add Baca dokumen lengkapnya